Is palbociclib chemotherapy. Results also indicate that palbociclib can extend the duration of disease control and can produce tumour shrinkage in patients with oestrogen-receptive positive breast cancer without the side effects associated with chemotherapy. Palbociclib is the drug’s non-branded name. Learn about side effects, cost, dosage, and more. When used to treat breast cancer, palbociclib is taken alongside hormone (endocrine) therapy. Ibrance treats HR-positive, HER2-negative advanced/metastatic breast cancer with aromatase inhibitors or fulvestrant. Its brand name is Ibrance. Palbociclib This leaflet is given in addition to your consent form(s) and booklet, 'Chemotherapy - a guide for patients and their carers'. It is made in a laboratory. [6] showed that oral administration of PD 0332991 to mice produced marked tumor regression in a broad spectrum of human tumor xenografts in vivo. View Palbociclib’s uses, side-effects, drug interactions, expert advice and user FAQs only on 1mg. [17] Leukopenia and anemia are also frequent among patients taking palbociclib. Learn about its side effects, cost, dosage, and more. This guidance updates and replaces NICE technology appraisal guidance 619 on palbociclib with fulvestrant for treating View Palbociclib [Specialist drug] information, including dose, uses, side-effects and important safety information. Palbociclib is a targeted or biological therapy drug. It works by blocking a protein that causes cancer cells to grow and multiply. It belongs to a group of drugs called CDK (cyclin dependent kinase) inhibitors. com. Ibrance (palbociclib) is a capsule or tablet you take by mouth to treat certain types of breast cancer, specifically hormone receptor-positive, human epidermal growth factor 2-negative (HR+, HER2‑) advanced or metastatic breast cancer. Ibrance (palbociclib) is a brand-name prescription medication used to treat certain types of breast cancer. Simply take your next dose at the regularly sch Be sure to write down if you miss a dose and let your care provider know about any missed doses. Learn about side effects, cost, how it compares to chemotherapy, uses, and more. Patients with non-Hodgkin’s lymphoma and/or Rb+ advanced solid tumor were eligible for this study. Palbociclib combinations may constitute viable replacements for chemotherapy in the neoadjuvant setting as part of de-escalation strategies. It blocks CDK4 and CDK6 proteins that promote cell growth and is used with other medications, such as hormone therapies. Find side effects, allergic reactions, and food and drug interactions. Ibrance (palbociclib) is an anti-cancer agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with other endocrine-based drug therapy. Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)‑negative, locally advanced or metastatic (secondary) breast cancer in adults. By inhibiting this protein, palbociclib causes the cell to stop actively dividing (growing). This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions. Palbociclib (Other Names: Ibrance®) is given by mouth to treat cancer. Learn about uses, side effects, drug interactions, dosages, warnings, and more. Also treats PIK3CA-mutated, endocrine-resistant breast cancer combined with inavolisib and fulvestrant after adjuvant therapy recurrence. Once inside cancer cells, Palbociclib can prevent cells from dividing and making new cancer cells. Palbociclib is a type of targeted therapy drug called a kinase inhibitor. 🧬💊 What are the side effects of this treatment? The following table lists side effects that you may have when getting palbociclib. HER2-negative breast cancer is treated with surgery, radiation, and/or medication, like chemotherapy, hormone or targeted therapy, or immunotherapy. Palbociclib is a type of oral, targeted cancer therapy called a “cyclin D kinase inhibitor. Your doctor will explain to you whether you will receive chemotherapy or another type of treatment, or a combination of both. We are developing guidance on palbociclib with Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). Learn about Palbociclib, a CDK4/6 inhibitor for hormone receptor-positive, HER2-negative breast cancer. It is a small-molecule drug (a drug that can enter cells easily). It must be made clear to all staff, including those in the community, that palbociclib should only be prescribed under the supervision of a consultant oncologist. However, the addition of palbociclib carries the risk of severe and treatment-limiting myelosuppression for the majority of patients. It treats breast cancer, which occurs when cells in your breast grow and divide in an uncontrolled way. Palbociclib is a selective inhibitor of the cyclin-dependent kinases 4 and 6 Home » Treatment & Care » Frequently Asked Questions about Ibrance (palbociclib) Generic Name: palbociclib Trade Name: Ibrance® For which conditions Ibrance drug approved? Ibrance is indicated for the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer in combination with: Palbociclib is used in the treatment of Breast cancer. The cost includes The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others it may control the cancer and its symptoms. An interim analysis of the PALOMA3 trial shows that women with hormone receptor-positive metastatic breast cancer who received palbociclib plus fulvestrant had longer progression-free survival rates than women who received a placebo plus fulvestrant. Blocking these proteins may slow or stop the growth of cancer cells. This review comprehensively highlights the pharmacological significance of palbociclib and its recently developed derivatives, focusing on mechanisms of action, chemical synthesis strategies Palbociclib is an endocrine-based chemotherapeutic agent used in combination with other antineoplastic agents to treat HER2-negative and HR-positive advanced or metastatic breast cancer. gov Identifier NCT01864746), non–small cell lung cancer (NCT0254490), glioblastoma Palbociclib (Ibrance) is a targeted therapy approved to treat hormone receptor-positive, HER2-negative metastatic breast cancer. Palbociclib is a chemotherapy drug used to treat HER2-negative and HR-positive breast cancers in women and men, which are advanced or have spread to other organs (metastatic), in combination with an anti-estrogenic drug. While drugs such as docetaxel and palbociclib also induced senescence, they did not trigger the same TGFβ-enriched SASP. A majority of patients taking palbociclib experience neutropenia, a condition where a patient has an abnormally low number of neutrophils. This side effect impacts the immune system, and is thus likely responsible for the second most common side effect, infection. Learn more about BC Cancer Palbociclib is not chemotherapy it is a targeted treatment (see: Is Ibrance a form of chemo? for more information). This comprehensive article delves into its pharmacodynamics, safety, and ongoing research. If you are unable to swallow palbociclib, talk to your care provider or pharmacist for possi t one time. This helps to slow or stop the spread of cancer cells. Palbociclib was associated with longer iDFS in the group who received prior anthracycline-paclitaxel chemotherapy (AC-P), though the chemo regimen x palbociclib interaction term was not significant (Table 1). Schwartz et al 65 conducted the first Phase I study of palbociclib in humans to determine maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of the 2/1 schedule of palbociclib treatment (2 weeks once daily and 1 week off treatment). We evaluated the respective efficacy and safety of chemotherapy and letrozole–palbociclib (LETPAL) combination as neoadjuvant treatment in patients with high-risk LBC. Fry et al. COMMON BRAND NAME (S Palbociclib works by blocking the activity of proteins called CDK4 and CDK6 that control how fast cells grow. Palbociclib interacts with many other agents. [17] More than 10% of patients also experience side BC Cancer’s mandate covers the full spectrum of cancer care from prevention, screening, diagnosis and treatment, to research and education, to supportive and palliative care. Learn about side effects, interactions, and uses. Palbociclib is a potent oral inhibitor of CDK4 and CDK6 that prevents the downstream phosphorylation of Rb, thereby leading to G1 arrest. ” Another name for this medicine is Ibrance. Dec 23, 2025 · Ibrance (chemical name: palbociclib) is used to treat advanced-stage or metastatic, hormone receptor-positive, HER2-negative breast cancer. Palbociclib is available under the following different brand names: Ibrance. Ibrance (palbociclib) is a targeted treatment that helps to reduce the growth and spread of cancer cells in the body. dissolved. See risks and benefits. Ibrance (palbociclib) is prescribed for a certain form of breast cancer. Explore the mechanisms, efficacy, and implications of palbociclib in cancer therapy. Palbociclib works by blocking the activity of proteins called CDK4 and CDK6 that control how fast cells grow. Palbociclib is a type of targeted cancer drug. Palbociclib is a selective cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor that emerged as a significant therapeutic agent in the treatment of hormone receptor-positive, HER2-negative breast cancer. Jan 28, 2026 · On the basis of preclinical and clinical data, the addition of palbociclib (a selective inhibitor of cyclin-dependent kinases 4 and 6) may overcome resistance to both endocrine and HER2-directed What is this medication? PALBOCICLIB (PAL boe SYE klib) treats breast cancer. Ibrance (palbociclib) is a prescription drug used to treat certain kinds of breast cancer. Additional Information The National Patient Safety Alert on oral chemotherapy (NPSA/2008/RRR001) must be followed in relation to palbociclib. Ibrance may be used to treat advanced or metastatic breast cancer in women with HR-positive, HER2-negative disease and is usually given when cancer has progressed or spread to other parts of the body despite other treatments. Capsules or tablets should be swallowed whole and not chewed, crushed, opened, or split prior to administration. Explore dosage, side effects, cost, and patient reviews. Palbociclib capsules should be administered with food; palbociclib tablets may be given with or without food. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. Results Table 1 summarizes the efficacy of adjuvant palbociclib by prior (neo)adjuvant chemotherapy regimen. Deregulation of the cell cycle is a hallmark of cancer, and research on cell cycle control has allowed identification of potential targets for anticancer treatment. The TOUCH trial showed that palbociclib and letrozole combined with dual anti-HER2 therapy achieved similar pCR rates to paclitaxel in HR-positive/HER2-positive early breast cancer. The table is set up to list the most common side effects first and the least common last. It is a treatment for locally advanced or advanced breast cancer. This medicine dissolves in your digestive system and gets absorbed into your blood. Find patient medical information for Ibrance (palbociclib) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings Palbociclib is used in combination with another medication as an initial treatment for a certain type of hormone receptor–positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) that has spread to other parts of the body. Palbociclib Adult Medication This information from Lexicomp ® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. The tumor-promoting response was most pronounced with platinum chemotherapy. In addition to confirmatory studies to explore the role of palbociclib in combination with antiestrogen therapy and/or chemotherapy in MBC, trials are underway in other clinical settings and diseases, including early-stage breast cancer (ClinicalTrials. Palbociclib is used to treat a certain type of breast cancer. Palbociclib stops cancer cells from growing. Palbociclib (Ibrance®) is a targeted therapy drug that is used to treat some types of breast cancer. Investigation into synergy of palbociclib with immunotherapies is also ongoing based on non-canonical effects of CDK4/6 inhibition on the tumor immune microenvironment. Palbociclib gained FDA approval on February 3, 2015, under the brand Ibrance. If a patient vomits or misses a dose, an extra dose should not be taken to make up for the vomited or missed dose. Notes: Palbociclib is given in combination with hormonal therapy. This “21-Day on, 7-Day off” treatment period is known as one Cycle Palbociclib should be taken with food but at the same time each day. . Jun 16, 2025 · Ibrance is a targeted drug therapy for advanced hormone receptor-positive breast cancer. Palbociclib seems to extend progression-free survival when added to letrozole or fulvestrant in women who have hormone-receptor-positive and HER2-negative advanced or metastatic breast cancer. Schedule How is palbociclib + letrozole therapy for breast cancer taken? Palbociclib usual starting dose: 125 mg oral capsule or tablet by mouth daily for 21 consecutive days, followed by a 7-day no palbociclib rest period. Learn about the IBRANCE® (palbociclib) combination regimens for certain patients with HR+/HER2- Metastatic Breast Cancer. See Indications and patient population section below Drug status: Palbociclib is PBS authority Palbociclib is available as 75 mg, 100 mg and 125 mg capsules or tablets Cost: ~ $3,650 per cycle The cost displayed on the protocol is an estimated cost intended as rudimentary guide only for the Australian context. How does palbociclib + fulvestrant work? Palbociclib is a targeted therapy designed to inhibit a specific protein that is responsible for turning off tumor suppressor genes and allowing the cancer cell to grow and divide. Some of these side effects may also be from other hormonal therapy that is given with palbociclib. Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. villdh, atqn, rw4mf, kjy7d, 4axu, qrtbbs, rdt5, nrift, 14rtk, jgaat,